<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347581</url>
  </required_header>
  <id_info>
    <org_study_id>hms0304</org_study_id>
    <nct_id>NCT00347581</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of Base-in Prism Reading Glasses Convergence Insufficiency in Children</brief_title>
  <official_title>A Randomized Clinical Trial of the Effectiveness of Base-in Prism Reading Glasses Vs. Placebo Reading Glasses for Symptomatic Convergence Insufficiency in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennsylvania College of Optometry</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pennsylvania College of Optometry</source>
  <brief_summary>
    <textblock>
      This study is designed to compare the use of special prism glasses to placebo treatment for&#xD;
      children with symptomatic convergence insufficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Base-in for Convergence Insufficiency Treatment Trial (BI-CITT) is a multi-center,&#xD;
      placebo-controlled, masked, clinical trial designed to compare the benefits of base-in prism&#xD;
      for patients with convergence insufficiency (CI).&#xD;
&#xD;
      The goals of this clinical trial are:&#xD;
&#xD;
        -  To compare the effectiveness of Base-in prism and Placebo eyeglasses for the treatment&#xD;
           of CI in children&#xD;
&#xD;
        -  To study the long-term effect of these treatments for CI&#xD;
&#xD;
        -  To identify factors that may be associated with successful treatment of CI with base-in&#xD;
           prism&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date>August 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom score on the Convergence Insufficiency Symptom Survey</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Near point of convergence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive fusional vergence at near</measure>
  </secondary_outcome>
  <enrollment>72</enrollment>
  <condition>Convergence Insufficiency</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Base-in prism glasses for reading</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo reading glasses</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 9 to &lt;19 years.&#xD;
&#xD;
          -  Best corrected visual acuity of ≥20/25 in each eye at distance and near&#xD;
&#xD;
          -  Willingness to wear eyeglasses or contact lenses to correct refractive error, if&#xD;
             necessary&#xD;
&#xD;
          -  Willingness to wear glasses for reading and other near work&#xD;
&#xD;
          -  Exophoria at near at least 4 greater than at far&#xD;
&#xD;
          -  Insufficient positive fusional convergence (fails Sheard's criterion)&#xD;
&#xD;
          -  Receded near point of convergence of  6 cm break&#xD;
&#xD;
          -  Random dot stereopsis appreciation using a 500 seconds of arc target.&#xD;
&#xD;
          -  CI Symptom Survey score  16&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Amblyopia (&gt; 2 line difference in best corrected visual acuity between the two eyes).&#xD;
&#xD;
          -  Constant strabismus&#xD;
&#xD;
          -  History of strabismus surgery.&#xD;
&#xD;
          -  Anisometropia  2D in any meridian between the eyes.&#xD;
&#xD;
          -  Prior refractive surgery.&#xD;
&#xD;
          -  Vertical heterophoria greater than 1 .&#xD;
&#xD;
          -  Systemic diseases known to affect accommodation, vergence and ocular motility such as:&#xD;
             multiple sclerosis, Graves thyroid disease, myasthenia gravis, diabetes, Parkinson&#xD;
             disease.&#xD;
&#xD;
          -  Any ocular or systemic medication known to affect accommodation or vergence&#xD;
             (Anti-anxiety agents (Librium or Valium), Anti-arrhythmic agents (Cifenline or&#xD;
             Cibenzoline), Anticholinergics (Motion sickness patch (scopolamine), Bladder&#xD;
             spasmolytic drugs (Propiverine), Chloroquine, Phenothiazines (Compazine, Mellaril, or&#xD;
             Thorazine), Tricyclic antidepressants (Elavil, Nortriptyline, or Tofranil)&#xD;
&#xD;
          -  Accommodative amplitude &lt;5 D in either eye as measured by the Donder's push-up method.&#xD;
&#xD;
          -  Manifest or latent nystagmus.&#xD;
&#xD;
          -  Developmental disability, mental retardation, attention deficit hyperactivity disorder&#xD;
             (ADHD), or learning disability diagnosis in children that in the investigator's&#xD;
             discretion would interfere with treatment.&#xD;
&#xD;
          -  Household member or sibling already enrolled in the BI-CITT.&#xD;
&#xD;
          -  Any eye care professional, ophthalmic technician, ophthalmology or optometry resident&#xD;
             or optometry student.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Scheiman, OD</last_name>
    <role>Study Chair</role>
    <affiliation>Pennsylvania College of Optometry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama, Birmingham, College of Optometry</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California College of Optometry</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NOVA College of Optometry</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University College of Optometry</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York, College of Optometry</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University, Optometry Coordinating Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Institute, Pennsylvania College of Optometry</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Houston, College of Optometry</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://optometry.osu.edu/research/CITT/</url>
    <description>Study Website</description>
  </link>
  <results_reference>
    <citation>Scheiman M, Cotter S, Rouse M, Mitchell GL, Kulp M, Cooper J, Borsting E; Convergence Insufficiency Treatment Trial Study Group. Randomised clinical trial of the effectiveness of base-in prism reading glasses versus placebo reading glasses for symptomatic convergence insufficiency in children. Br J Ophthalmol. 2005 Oct;89(10):1318-23.</citation>
    <PMID>16170124</PMID>
  </results_reference>
  <verification_date>January 2005</verification_date>
  <study_first_submitted>July 3, 2006</study_first_submitted>
  <study_first_submitted_qc>July 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>July 3, 2006</last_update_submitted>
  <last_update_submitted_qc>July 3, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2006</last_update_posted>
  <keyword>convergence insufficiency</keyword>
  <keyword>base-in prism</keyword>
  <keyword>orthoptics</keyword>
  <keyword>vision therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocular Motility Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

